Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/eji.202149374 http://scihub22266oqcxt.onion/10.1002/eji.202149374 34355795!8420377!34355795     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34355795&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Immunol 2022 ; 52 (5): 770-783 Nephropedia Template TP {{tp|p=34355795|t=2022. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model |pdf=|usr=}}{{34355795}} gab.com Text A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model JO: Eur J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34355795 #FOAvip TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives. Twit Text FOAVip A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model ????Eur J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34355795 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34355795 #FOAvip English Wikipedia <ref>{{Cite pmid|34355795}}</ref> A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model #MMPMID34355795 Peter AS; Roth E; Schulz SR; Fraedrich K; Steinmetz T; Damm D; Hauke M; Richel E; Mueller-Schmucker S; Habenicht K; Eberlein V; Issmail L; Uhlig N; Dolles S; Gruner E; Peterhoff D; Ciesek S; Hoffmann M; Pohlmann S; McKay PF; Shattock RJ; Wolfel R; Socher E; Wagner R; Eichler J; Sticht H; Schuh W; Neipel F; Ensser A; Mielenz D; Tenbusch M; Winkler TH; Grunwald T; Uberla K; Jack HM Eur J Immunol 2022[May]; 52 (5): 770-783 PMID34355795show ga TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives. |*COVID-19[MESH] |*Spike Glycoprotein, Coronavirus[MESH] |Animals[MESH] |Antibodies, Monoclonal[MESH] |Antibodies, Neutralizing[MESH] |Antibodies, Viral[MESH] |Humans[MESH] |Mice[MESH]A pair of noncompeting neutralizing human monoclonal antibodies protec(epmc).pdf DeepDyve Pubget Overpricing